drugset
drugset / Trial / NCT03575676

Efficacy and Safety of SOM3355 in Huntington's Disease Chorea

NCT03575676 ↗

Phase 2 Completed 32 enrolled SOM Innovation Biotech SA
RandomizedCrossoverQuadruple-blindTreatment

Summary

Phase IIa study to evaluate the efficacy and safety of SOM3355 in chorea movements associated with Huntington's disease

Timeline

Start
2018-08-08
Primary completion
2019-08-22
Completion
2019-08-22

Outcome

Met primary endpoint

paper The primary endpoint was met in 57.1% of the patients. PMID 36494329 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BEVANTOLOL Small molecule 100 mg Oral
Subject BEVANTOLOL Small molecule 200 mg Oral

Indications

Huntington disease